medigraphic.com
ISSN 1025-0255 (Electronic)

2017, Number 2

<< Back Next >>

AMC 2017; 21 (2)

Therapeutic response in patients with polycistic ovary syndrome

González RA, González GF, Coll BD, Figueredo TN, Ramos AU, Cabrera FI

Language: Spanish
References: 30
Page: 191-201
PDF size: 933.77 Kb.


ABSTRACT

Background: polycystic ovary syndrome is an heterogeneous disorder; it has been recognized as the main cause of infertility on women during reproductive ages.
Objective: to determine the therapeutic response in patients suffering from polycystic ovary syndrome in Camaguey hospital "Manuel Ascunce Domenech" at endocrinology consultation from January 2013 to January 2015. Methods: an observational descriptive and longitudinal study was carried out. The universe was sample by all patients who were diagnosed with polycystic ovary syndrome. The data were processed by descriptive statistics.
Results: 66, 97 % of patients answered to the treatment and 70, 00 % of patients who had normoandrogenic type answered correctly too. After the treatment 55, 50 % of patients continuous with ovary volume higher than 13 mL.
Conclusions: the most important variation were to reduce blood levels of testosterone and to increase blood levels of progesterone. The therapeutic combination more used was hygienic-dietetic changes plus metformina.


REFERENCES

  1. Jara Díaz JF de la, Ortega González C. Síndro-me de ovario poliquístico. Rev Mex Med Repro-duc [Internet]. 2011 [citado 5 May 2013];4(2):[aprox. 7 p.]. Disponible en: http://www.medigraphic.com/pdfs/reproduccion/mr-2011/mr112b.pdf

  2. Petríková J, Lazúrová I, Shoenfeld Y. Polycys-tic ovary syndrome and Autoimmunity. New York: Raven Press; 1995.

  3. Diamanti Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endoc Rev [Internet]. 2012 Dec [citado 2013 May 5];33(6):[about 4 p.]. Available from: http://press.endocrine.org/doi/pdf/10.1210/er.2011-1034

  4. Laven J, Imani B, Eijkemans MJ, Fauser BC. New Approach to Polycystic Ovary Syndrome and Other Forms of Anovulatory Infertility. Obstet Gynecol Surv. 2002 Nov;57(11):755-67.

  5. Bentley Lewis R, Seely E, Dunaif A. Ovarian Hypertension: polycystic ovary syndrome. Endo-crinol Metab Clin North Am [Internet]. 2011 Jun [citado 2013 May 5];40(2):[about 11 p.]. Availa-ble from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3253555/.

  6. Florez JC. Genetic Susceptibility for Polycystic Ovary Syndrome on Chromosome 19: advances in the genetic dissection of complex reproductive traits. J Clin Endocrinol Metab [Internet] 2005 Dec [citado 2013 May 5];90(12):[about 12 p.]. Available from: http://press.endocrine.org/doi/10.1210/jc.2005-2204?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed

  7. Monteagudo Peña G. Diagnóstico y tratamien-to del síndrome de ovarios poliquísticos. La Ha-bana: Curso de actualización de Endocrinología; 2011.

  8. López Iñiguez A. Síndrome de Ovário Poliquís-tico. Rev Méd [Internet]. 2010 [citado 5 May 2013];6(1):[aprox. 7 p.]. Disponible en: http://www.medigraphic.com/pdfs/revmed/md-2010/md106d.pdf

  9. Checa Vizcaíno MA. Síndrome del ovario poli-quístico. Médica Panamericana. 2005;24(2):182.

  10. Sir-Petermann T. Síndrome de ovario poli-quístico: la importancia de establecer su diag-nóstico. Rev Méd Chile. 2011;129(7):42-53.

  11. Acosta Cedeño A, Monteagudo Peña G, Menocal Alayón A. Patrón hormonal de mujeres con diagnóstico clínico y ecográfico del síndrome de ovarios poliquísticos. Rev Cubana Endocrinol [Internet]. Ago 2004 [citado 2 Feb 2015];5(2):[aprox. 6 p.]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-29532004000200003&lng=es.

  12. Espinoza Alvarado C, Matute García NC, Ochoa Rueda S, López Lutz E. Caracterización clínica de pacientes con Síndrome de Ovario poli-quístico. Rev Méd Hondur [Internet]. 2011 [citado 2 Feb 2015];79(3):[aprox. 5 p.]. Dispo-nible en: http://www.bvs.hn/RMH/pdf/2011/pdf/Vol79-3-2011-5.pdf

  13. Dokras A. Cardiovascular disease risk in wom-en with PCOS. Steroids. 2013 Aug;78(8):773-6.

  14. Guo M, Chen ZJ, Eijkemans MJ, Goverde AJ, Fauser BC, Macklon NS.Comparison of the phe-notype of Chinese versus Dutch Caucasian wom-en presenting with polycystic ovary syndrome and oligo/amenorrhea. Hum Reprod [Internet]. 2012 May [citado 2015 Feb 2];27(5):[about 10 p.]. Available from: http://humrep.oxfordjournals.org/content/27/5/1481.long

  15. Fux C. Síndrome de ovario poliquístico: revi-sión de su fisiopatogenia. Rev Fac Cienc Méd. 2013;70(1):27-30.

  16. Rodrigo Carvajal G, Cristian Herrera G, Ar-naldo Porcile J. Espectro fenotípico del Síndrome de Ovario Poliquístico. Rev chilena obstetr gine-col. 2010;75(2):124-32.

  17. Pellatt L, Rice S, Mason HD. Anti-Müllerian hormone and polycystic ovary syndrome: a mountain too high? Reproduction. 2010 May;139(5):825-33.

  18. Bungum L, Franssohn F, Bungum M, Humai-dan P, Giwercman A. The circadian variation in Anti-Mullerian hormone in patients with polycys-tic ovary syndrome differssignificantly from nor-mally ovulating women. PLoS One [Internet]. 2013 Sep 4 [citado 2015 Feb 2];8(9):[about 5 p.]. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3762839/.

  19. Witherby S, Johnson J, Demers L, Mount S, Littenberg B, Maclean CD, et al. Topical testos-terone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study. Oncologist [Internet]. 2011 [citado 2015 Feb 2];16(4):[about 12 p.]. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3228118/.

  20. Azziz R, Carmina E, Dewailly D, Diamanti Kandarakis E, Escobar Morreale HF, Futterweit W, et al. Criteria for definig polycystic ovary syn-drome as a predominantly hyperandrogenic syn-drome: an Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006 Nov;91(11):4237-45.

  21. Davis SR, Panjari M, Stanczyk FZ. DHEA re-placement for postmenopausal women. J Clin Endocrinol Metab [Internet]. 2011 [citado 2015 Feb 2];96(6):[about 14 p.]. Available from: http://press.endocrine.org/doi/full/10.1210/jc.2010-2888

  22. Elraiyah T, Sonbol MB, Wang Z, Khairalseed T, Asi N, Undavalli C, et al. Clinical review: The benefits and harms of systemic testosterone the-rapy in postmenopausal women with normal adrenal function: a systematic review and meta-analysis. J Clin Endocrinol Metab [Internet]. 2014 [citado 2015 Feb 2];99(10):[about 8 p.]. Available from: http://press.endocrine.org/doi/10.1210/jc.2014-2262?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed

  23. Fernandes T, Costa Paiva LH, Pinto Neto AM. Efficacy of vaginally applied estrogen, testostero-ne, or polyacrylic acid on sexual function in post-menopausal women: a randomized controlled trial. J Sex Med [Internet]. 2014 May [citado 2015 Feb 2];11(5):[about 7 p.]. Available from: http://www.pubfacts.com/detail/24612478/Efficacy-of-vaginally-applied-estrogen-testosterone-or-polyacrylic-acid-on-sexual-function-in-postme

  24. Haring R, Hannemann A, John U, Radke D, Nauck M, Wallaschofski H, et al. Age-specific ref-erence ranges for serum testosterone and an-drostenedione concentrations in women meas-ured by liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab [Internet]. 2012 Feb [citado 2015 Feb 2];97(2):[about 12 p.]. Available from: http://press.endocrine.org/doi/10.1210/jc.2011-2134?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed

  25. Dipankar B, Salil Kumar M, Satinath M, Ma-mata P. Clinical correlation with biochemical sta-tus in polycystic ovarian syndrome. J Obstet Gy-necol India [Internet]. 2005 [citado 2015 Feb 2];55(1):[about 8 p.]. Available from: http://medind.nic.in/jaq/t05/i1/jaqt05i1p67.pdf

  26. Ovies Carballo G, Domínguez Alonso E, Ver-deja Varela OL, Zamora Recinos H. Frecuencia y características clínicas, hormonales y ultrasono-gráficas sugestivas de síndrome de ovarios poli-quísticos en un grupo de mujeres con síndrome metabólico. Rev Cubana Endocrinol. 2008;19(3):20-24.

  27. Bonilla-Musoles F, Castillo Farfán JC, Raga F, Bonilla F, Caballero Luna O. Alta definición eco-gráfica en tiempo real (HDLive US) en Obstetricia y Ginecología. Rev Per Ginecol Obstet. 2013;59(1):407-13.

  28. Carmina E, Campagna AM, Lobo RA. A 20-year followup of young women with polycystic ovary syndrome. Obstet Gynecol. 2012;119(2 Pt 1):263-9.

  29. Cabrera Gamez M. Tratamiento con sensibili-zadores de insulina en el SOP. Consenso Síndro-me de Ovarios Poliquísticos. La Habana: Instituto Nacional de Endocrinología; 2015.

  30. Rodríguez Flores M. Síndrome de ovario poli-quístico: el enfoque del internista. Med Int Mex [Internet]. 2012 [citado 5 May 2013];28(1):[aprox. 8 p.]. Disponible en: http://www.medigraphic.com/pdfs/medintmex/mim-2012/mim121h.pdf




2020     |     www.medigraphic.com